4
Changes in Ownership
Cartesian Therapeutics, Inc. Filed Acc 0001453687-24-000128
Chief Scientific Officer sold 52,115 shares at an average $16.79 ($875,042)
- Chief Scientific Officer acquired 52,115 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Jewell Christopher M Chief Scientific Officer | 2024-11-14 | Option exercise | +36,050 | $3.23 | $116,442 | 61,990 | D |
| Jewell Christopher M Chief Scientific Officer | 2024-11-14 | Sale | −18,550 | $16.34 | $303,126 | 43,440 | D |
| Jewell Christopher M Chief Scientific Officer | 2024-11-14 | Sale | −17,500 | $17.02 | $297,824 | 25,940 | D |
| Jewell Christopher M Chief Scientific Officer | 2024-11-15 | Option exercise | +16,065 | $3.23 | $51,890 | 42,005 | D |
| Jewell Christopher M Chief Scientific Officer | 2024-11-15 | Sale | −16,065 | $17.06 | $274,093 | 25,940 | D |
| Derivatives | |||||||
| Jewell Christopher M Chief Scientific Officer | 2024-11-14 | Option exercise · Stock Option (Right to Buy) | −36,050 | 106,497 | D | ||
| Jewell Christopher M Chief Scientific Officer | 2024-11-15 | Option exercise · Stock Option (Right to Buy) | −16,065 | 90,432 | D | ||
| Open-market sales · 52,115 sh · avg $16.79 · $875,042 | |||||||
Loading xslF345X05/wk-form4_1731975821.xml…